Sofosbuvir and peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients
New results demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 26, 2015 Category: Science Source Type: news

Statins Show Benefit in Hepatitis C Compensated CirrhosisStatins Show Benefit in Hepatitis C Compensated Cirrhosis
Statins, long thought to be hepatotoxic in patients with advanced liver disease, might actually slow decompensation and prolong survival, but a randomized trial is needed to prove it. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 25, 2015 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Drinking just 1 or 2 alcoholic drinks a day linked to liver disease
(European Association for the Study of the Liver) According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver CongressTM 2015 has shown the significant influence of daily drinking on this disease burden. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2015 Category: Global & Universal Source Type: news

DCV, SOF & RBV comb. effective/tolerated in HCV with adv, cirrhosis / post-transplant recurrence
(European Association for the Study of the Liver) Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2015 Category: Global & Universal Source Type: news

Sofosbuvir + peginterferon/ribavirin demonstrates virologic response rates in G3 hep C patients
(European Association for the Study of the Liver) Results presented today at The International Liver Congress™ 2015 demonstrate that hepatitis C (HCV)-infected genotype-3 (GT-3) patients, with and without cirrhosis, receiving 24 weeks of sofosbuvir (SOF) in combination with ribavirin (RBV) and peginterferon (PEG) achieved the highest sustained virologic response rates at 12 weeks (SVR12), observed in a Phase 3 study, to date. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 25, 2015 Category: Global & Universal Source Type: news

Liver Cirrhosis: Inpatient Mortality Is DecreasingLiver Cirrhosis: Inpatient Mortality Is Decreasing
In-hospital mortality is decreasing for patients with cirrhosis, but outpatient mortality is unclear. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 24, 2015 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Merck’s Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection
Dateline City: VIENNA Data Sets Include Treatment-Naïve, Treatment-Experienced and HIV Co-Infected Patients with Chronic Hepatitis C Virus Genotypes 1, 4 or 6 Infection Merck Remains on Track to Submit New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) in First Half of 2015 VIENNA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentations of data from the company’s ongoing C-EDGE pivotal Phase 3 clinical trial program evaluating the investigational once-daily table...
Source: Merck.com - Research and Development News - April 24, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news

Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease
Dateline City: VIENNA C-SURFER Trial is First to Investigate an All-Oral Ribavirin-Free Hepatitis C Treatment Regimen in Treatment-Naïve and Treatment-Experienced Patients with Advanced Chronic Kidney Disease Infected with Hepatitis C Virus Genotype 1 VIENNA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data from C-SURFER, the company’s Phase 2/3 clinical trial evaluating the investigational once-daily treatment regimen of grazoprevir (100mg...
Source: Merck.com - Research and Development News - April 23, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News Source Type: news

All-oral, DAA options for HCV effective & well tolerated in patients with decompensated cirrhosis
(European Association for the Study of the Liver) Interim data presented today at The International Liver CongressTM 2015 from the HCV-TARGET study show that all-oral, direct-acting antiviral therapy for hepatitis C is well tolerated and highly effective in patients with decompensated cirrhosis. Sustained virologic response at four weeks was shown to be: sofosbuvir/ribavirin: 75 percent; sofosbuvir/simeprevir: 77 percent; sofosbuvir/simeprevir/ribavirin: 81 percent. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 23, 2015 Category: Biology Source Type: news

Lupin launches anti-bacterial Zaxine tablets in Canada
Zaxine 550 mg (rifaximin) is a long-term antibiotic treatment drug for adults living with HE, a complication of liver disease (cirrhosis). (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 20, 2015 Category: Pharmaceuticals Source Type: news

Alkaline Phosphatase, Bilirubin Levels and Outcomes in PBCAlkaline Phosphatase, Bilirubin Levels and Outcomes in PBC
Do alkaline phosphatase and bilirubin levels help clinicians predict disease outcome in patients with primary biliary cirrhosis? Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 20, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Mouth, as well as gut, could hold key to liver disease flare-ups
In a recent study, researchers predicted which cirrhosis patients would suffer inflammations and require hospitalization by analyzing their saliva, revealing a new target for research into a disease that accounts for more than 30,000 deaths in the United States each year. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 17, 2015 Category: Science Source Type: news

Mouth, as well as gut, could hold key to liver disease flare-ups
(Virginia Commonwealth University) In a recent study, Virginia Commonwealth University School of Medicine researchers predicted which cirrhosis patients would suffer inflammations and require hospitalization by analyzing their saliva, revealing a new target for research into a disease that accounts for more than 30,000 deaths in the United States each year. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 17, 2015 Category: Global & Universal Source Type: news

The CNIO links telomeres to the origins of liver diseases such as chronic hepatitis and cirrhosis
This study is the first to show that alterations in the functioning of telomeres lead to changes in the liver that are common to diseases associated with an increased risk of liver cancer. This finding provides the basis for understanding the molecular origin of these diseases, as well as identifying new therapeutic strategies for their prevention and control. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 16, 2015 Category: Cancer & Oncology Source Type: news

Alcohol Dependency in Our Family and How We Struggle With It
He was in his 50s when he died. We put all of his earthly possessions into three banana boxes and placed them into the trunk of our '63 Chevy station wagon. The key to the single (twin bed) hotel room was returned to the front desk clerk. Ironically, this was the same job he once held before alcohol got him too pickled to keep his balance for longer than half an hour. They said it was too hard for him to stand up. By the time I met Uncle Ivan he had probably been drinking (heavily) for the previous four decades. There was a certain odor about him that smelled of piss vinegar and Old Spice. I remember the whiskers on his ch...
Source: Healthy Living - The Huffington Post - April 11, 2015 Category: Consumer Health News Source Type: news

Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver CongressTM 2015
Dateline City: KENILWORTH, N.J. Congress Highlights Include Results from Trials in a Wide Range of HCV Patients -- Patients with Chronic Kidney Disease, HIV Co-infection, Cirrhosis, and Prior Treatment Failures Company Remains on Track for NDA Filing with the U.S. FDA During First Half of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HC...
Source: Merck.com - Corporate News - April 8, 2015 Category: Pharmaceuticals Tags: Hepatitis C Newsroom Corporate News Latest News Source Type: news

Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver CongressTM 2015
Dateline City: KENILWORTH, N.J. Congress Highlights Include Results from Trials in a Wide Range of HCV Patients -- Patients with Chronic Kidney Disease, HIV Co-infection, Cirrhosis, and Prior Treatment Failures Company Remains on Track for NDA Filing with the U.S. FDA During First Half of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection, has received two ...
Source: Merck.com - Corporate News - April 8, 2015 Category: Pharmaceuticals Tags: Corporate News Latest News Source Type: news

Standard nursing assessments improve ability to predict survival in cirrhosis patients
(Beth Israel Deaconess Medical Center) A new study from the Liver Center at Beth Israel Deaconess Medical Center suggests that standard assessments that nurses already use to care for patients can be mined for data that significantly improve the ability to predict survival following liver transplantation and may help improve patient outcomes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2015 Category: Global & Universal Source Type: news

Psychoactive medications increase the risk of falls and fall-related injuries in hospitalized patients with cirrhosis - Tapper EB, Risech-Neyman Y, Sengupta N.
BACKGROUND & AIMS: Reducing or eliminating falls are a focus of patient safety programs as well as health policy. Falls are tied to hospital reimbursement. However, little is known about the risk of falls among hospitalized patients with cirrhosis or facto... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - April 5, 2015 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news

Liver injury in non-alcoholic steatohepatitis leads to a leaky gut
Non-alcoholic steatohepatitis (NASH), the more severe form of non-alcoholic fatty liver disease that can progress to liver fibrosis and cirrhosis, is associated with leakiness of the intestinal wall, which in turn may worsen liver disease, according to research. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 2, 2015 Category: Science Source Type: news

New HCV Drugs Cost-effective for Some With Genotypes 2 and 3New HCV Drugs Cost-effective for Some With Genotypes 2 and 3
At $1000 a pill, interferon-free drugs are a good value for patients with cirrhosis who have not benefited from interferon; if lower prices cannot be negotiated, new drugs should go to the sickest. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 31, 2015 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

New genetic link found for alcohol-related liver cirrhosis
In most people, any liver damage that might occur from drinking alcohol is reversible. However, in 25 to 30 percent of alcoholics what begins as accumulation of fat in the liver progresses to inflammation, fibrosis and ultimately irreversible cirrhosis, for which the only treatment is a liver transplant. A new study indicates that specific gene mutations might predispose some people to irreversible liver cirrhosis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 30, 2015 Category: Science Source Type: news

Sofosbuvir Cost-Effective for Hepatitis C Genotype 2 or 3? Only in Certain Patients (FREE)
By Amy Orciari Herman Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH Sofosbuvir-based therapy is cost-effective in patients with hepatitis C genotype 2 or 3 infection plus cirrhosis and in those who've previously been treated with interferon, according to a simulation study … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 30, 2015 Category: Primary Care Source Type: news

Alterations in Cerebral White Matter and Neuropsychology in Patients with Cirrhosis and Falls - Gómez-Ansón B, Román E, Fernández de Bobadilla R, Pires-Encuentra P, Díaz-Manera J, Núñez F, Martinez-Horta S, Vives-Gilabert Y, Pagonabarraga J, Kulisevsky J, Córdoba J, Guarner C, Soriano G.
BACKGROUND & AIM: Falls are frequent in patients with cirrhosis but underlying mechanisms are unknown. The aim was to determine the neuropsychological, neurological and brain alterations using magnetic resonance-diffusion tensor imaging (MR-DTI) in cirrhot... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - March 28, 2015 Category: Global & Universal Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Beta-blockers, PPIs, and Bacterial Infections in CirrhosisBeta-blockers, PPIs, and Bacterial Infections in Cirrhosis
Are patients taking beta-blockers and PPIs more prone to bacterial infections in the presence of cirrhosis and, if so, why? Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

UCLA public health researchers go to church to promote hepatitis B screening
UCLA-Kaiser Permanente Center for Health Equity To reach a vulnerable population largely unaware of the health risks, a team from the Fielding School for Public Health held small group discussions in more than 50 Los Angeles-area Korean churches. For the large Korean American-community in Los Angeles, chronic infection with the hepatitis B virus looms as a significant — and too often unspoken — health threat, associated with the highest rates of liver cancer for any ethnic group in Los Angeles. Knowing one’s hepatitis B status can be critical — it allows those who test HBV-negative t...
Source: UCLA Newsroom: Health Sciences - March 21, 2015 Category: Universities & Medical Training Source Type: news

Love Your Liver And Turn Back The Years
Today, I want to talk to you about how important it is to be nice to your liver – especially if you want to keep your body younger than your years. And I’m not talking about cutting out that nice bottle of Bordeaux you might share with a special dinner companion on a Saturday night or depriving yourself of that fine, 18-year-old single malt you love to savor every now then. Of course, I recommend that you always drink responsibly. But if you really want to look after your liver, my advice is to drop excess fat. In fact, at my wellness clinic, taking good care of your liver by staying lean is one of my key anti-...
Source: Al Sears, MD Natural Remedies - March 13, 2015 Category: Complementary Medicine Authors: Dr. Al Sears Tags: Anti-Aging Nutrition DNA fat loss supplements toxins Source Type: news

WHO issues its first hepatitis B treatment guidelines
WHO today issued its first-ever guidance for the treatment of chronic hepatitis B, a viral infection which is spread through blood and body fluids, attacking the liver and resulting in an estimated 650 000 deaths each year – most of them in low- and middle-income countries. Worldwide, some 240 million people have chronic hepatitis B virus with the highest rates of infection in Africa and Asia. People with chronic hepatitis B infection are at increased risk of dying from cirrhosis and liver cancer. (Source: WHO news)
Source: WHO news - March 12, 2015 Category: Global & Universal Tags: hepatitis [subject], jaundice, hepatitis a, hepatitis b, hepatitis c, hepatitis e, hepatitis [subject], jaundice, hepatitis a, hepatitis b, hepatitis c, hepatitis e, Press release [doctype] Source Type: news

PPIs, Liver Disease, and Mortality in Patients With CirrhosisPPIs, Liver Disease, and Mortality in Patients With Cirrhosis
What does the latest research tell us about PPI use and the risk for severe liver disease and mortality in patients with cirrhosis? Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 9, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Cirrhosis Regression in HCV Patients After Antiviral TherapyCirrhosis Regression in HCV Patients After Antiviral Therapy
Do the majority of patients with cirrhosis who achieve a sustained virological response develop cirrhosis regression? This new study investigates. Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 2, 2015 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Finding the Patient With Primary Biliary CirrhosisFinding the Patient With Primary Biliary Cirrhosis
If you don't consider it, you might miss the diagnosis of this slowly progressive autoimmune disorder. Medscape Gastroenterology (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - February 28, 2015 Category: Gastroenterology Tags: Gastroenterology Expert Column Source Type: news

Researchers wind up a 40 year old debate on betaretrovirus infection in humans
New light has been shed on primary biliary cirrhosis, a rare liver disease that affects up to one in 500 middle aged women. In a study, researchers demonstrate that patients with the disease are infected with human betaretrovirus -- a virus resembling a mouse mammary tumor virus. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 19, 2015 Category: Science Source Type: news

UAlberta researchers wind up a 40-year-old debate on betaretrovirus infection in humans
(University of Alberta Faculty of Medicine & Dentistry) Research from the University of Alberta is shedding new light on primary biliary cirrhosis, a rare liver disease that affects up to one in 500 middle-aged women. In a study published in the journal Alimentary Pharmacology and Therapeutics, Andrew Mason, a professor of medicine in the Department of Medical Microbiology and Immunology, proves that patients with the disease are infected with human betaretrovirus -- a virus resembling a mouse mammary tumor virus. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 19, 2015 Category: Global & Universal Source Type: news

Learn about the impact of diet on diabetes, cancer and heart disease
The Nutrition Society’s next scientific conference on 25-26 March in Aberdeen, Scotland, will focus on Diet, Gene Regulation and Metabolic Disease, and brings together leading scientific speakers on these topics from around the world: Professor Donald B Jump, Nutrition Program, School of Biological and Population Health Sciences, Oregon State University, USA;    Professor Romano Regazzi, Vice-Director of the School of Medicine, Department of Fundamental Neurosciences, University of Lausanne, Switzerland; Professor Loranne Agius, Professor of Metabolic Biochemistry, Institute of Cellular Medicine, Newcastle ...
Source: The Nutrition Society - February 17, 2015 Category: Nutrition Authors: RB Source Type: news

Rwanda: Why You Must Test for Hepatitis
[New Times]It is more infectious than HIV. And like HIV, you can carry the Hepatitis virus for ages without knowing that you have it. But Hepatitis B and C are fatal and can lead to liver failure and death. If left untreated, Hepatitis can lead to cirrhosis, liver cancer, liver failure and death. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - February 16, 2015 Category: African Health Source Type: news

Smoking Causes More Kinds Of Deaths Than We Ever Thought
Breast cancer, prostate cancer, and even routine infections. A new report ties these and other maladies to smoking and says an additional 60,000 to 120,000 deaths each year in the United States are probably due to tobacco use. The study by the American Cancer Society and several universities, published in Thursday's New England Journal of Medicine, looks beyond lung cancer, heart disease and other conditions already tied to smoking, and the 480,000 U.S. deaths attributed to them each year. "Smokers die, on average, more than a decade before nonsmokers," and in the U.S., smoking accounts for one of every five de...
Source: Science - The Huffington Post - February 12, 2015 Category: Science Source Type: news

Daily Drinking May Raise Risk of Liver Cirrhosis, Study Warns
Title: Daily Drinking May Raise Risk of Liver Cirrhosis, Study WarnsCategory: Health NewsCreated: 1/27/2015 12:00:00 AMLast Editorial Review: 1/28/2015 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - January 28, 2015 Category: Nutrition Source Type: news

Daily Drinking May Raise Risk of Liver Cirrhosis, Study Warns
Everyday habits appear to matter more than lifetime consumption, research suggests (Source: WebMD Health)
Source: WebMD Health - January 27, 2015 Category: Consumer Health News Source Type: news

Daily Drinking May Raise Risk of Liver Cirrhosis
Everyday habits appear to matter more than lifetime consumption, research suggests Source: HealthDay Related MedlinePlus Pages: Alcoholism and Alcohol Abuse, Cirrhosis (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - January 27, 2015 Category: Consumer Health News Source Type: news

Daily drinking increases risk of alcoholic cirrhosis
(Elsevier Health Sciences) Approximately 170,000 people die from alcoholic cirrhosis of the liver in Europe every year. Although alcohol is the most important risk factor, less is known about the significance of different patterns of drinking. Currently scientists believe that cirrhosis is a function of the volume of alcohol consumed irrespective of patterns of drinking. Investigators have now established that alcohol drinking pattern has a significant influence on the risk of cirrhosis and that daily drinking increases that risk compared with drinking less frequently. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 26, 2015 Category: Global & Universal Source Type: news

January 20th Webinar Topic: Fatty Liver Disease and Liver Transplantation
Webinar Topic: Fatty Liver Disease and Liver Transplantation: For Adults and Children, What Patients Need to Know Join us on Tuesday, January 20th, 12:00 p.m CT to discuss the management of fatty liver disease in adults & children. Also learn about liver transplantation as a treatment for advanced disease and cirrhosis. Click on Mayo Clinic Connect [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 15, 2015 Category: Databases & Libraries Source Type: news

Viekirax and Exviera for the Treatment of Chronic Hepatitis C Virus Infection
Viekirax (ombitasvir / paritaprevir / ritonavir) and Exviera (dasabuvir) is indicated for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection and compensated cirrhosis. (Source: Drug Development Technology)
Source: Drug Development Technology - January 13, 2015 Category: Pharmaceuticals Source Type: news

Conatus Says Data Supports Moving Forward With Liver Disease DrugConatus Says Data Supports Moving Forward With Liver Disease Drug
Conatus Pharmaceuticals Inc said on Thursday initial results from small early stage trials supported continued development of its experimental drug for patients with cirrhosis and liver impairment. Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - January 9, 2015 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Study: more people have liver cirrhosis than previously thought
(NaturalNews) Researchers from the Loyola University Health System have discovered that liver cirrhosis, which can lead to liver cancer and liver failure, is more common than previously thought. After examining information from the National Health and Nutrition Examination Survey... (Source: NaturalNews.com)
Source: NaturalNews.com - January 9, 2015 Category: Consumer Health News Source Type: news

Biliary Cirrhosis Therapeutic Pipeline Review H2 2014 Report at...
ReportsnReports.com adds “Biliary Cirrhosis - Pipeline Review, H2 2014” to its store. The report provides an overview of the Biliary Cirrhosis therapeutic pipeline.(PRWeb January 05, 2015)Read the full story at http://www.prweb.com/releases/2014-h2-biliary-cirrhosis/pipeline-review-market/prweb12422863.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 6, 2015 Category: Pharmaceuticals Source Type: news

Liver cirrhosis more common than previously thought, study finds
(Loyola University Health System) Cirrhosis of the liver is more common than previously thought, affecting more than 633,000 adults yearly. And surprisingly, 69 percent of the adults identified as possibly having cirrhosis may not know they have the disease. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 5, 2015 Category: Global & Universal Source Type: news

Liver cirrhosis more common than previously thought, study finds
Cirrhosis of the liver is more common than previously thought, affecting more than 633,000 adults yearly. And surprisingly, 69 percent of the adults identified as possibly having cirrhosis may not know they have this disease, researchers report. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 4, 2015 Category: Science Source Type: news

Mechanics of cells' long-range communication modeled by researchers
Interdisciplinary research is showing how cells interact over long distances within fibrous tissue, like that associated with many diseases of the liver, lungs and other organs. By developing mathematical models of how the collagen matrix that connects cells in tissue stiffens, the researchers are providing insights into the pathology of fibrosis, cirrhosis of the liver and certain cancers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 23, 2014 Category: Science Source Type: news

Viekira Pak Approved for Hepatitis C (FREE)
By Amy Orciari Herman Edited by André Sofair, MD, MPH The FDA on Friday approved a new, all-oral, interferon-free treatment for patients with hepatitis C genotype 1, including those with cirrhosis. Viekira Pak includes a combination ombitasvir/paritaprevir/ritonavir tablet (two tablets taken once daily) plus a dasabuvir tablet … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 22, 2014 Category: Primary Care Source Type: news

FDA approves Viekira Pak to treat hepatitis C
The U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 19, 2014 Category: American Health Source Type: news